Discover the Latest in Cancer Immunotherapy from SITC
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) is thrilled to announce an incredible array of clinical abstract submissions for their forthcoming 40th Anniversary Annual Meeting. This year has seen a remarkable engagement with over 1,300 submissions, featuring a significant number of Late-breaking Abstracts that promise to showcase pioneering research and breakthroughs in immunotherapy.
What to Expect at the Upcoming Annual Meeting
The 40th Anniversary Annual Meeting, set to take place both in-person and virtually, is scheduled for November 5–9. Attendees can look forward to hearing from leading researchers and experts as they unveil cutting-edge data and findings in cancer treatment. "We are excited to incorporate these clinical abstracts into an already impressive lineup of presentations,” said SITC Vice President Sandra Demaria, MD. She emphasized the importance of sharing late-breaking clinical trial data that could revolutionize treatment approaches for cancer patients.
Engaging Presentations That Highlight Innovation
The Late-breaking Abstracts selected for oral presentations aim to deliver the latest insights from interventional clinical trials involving human participants. This focus on new data seeks to enhance discussions around progressive treatment methods and improve patient outcomes. Notably, SITC is on a mission to expedite the approval of 100 novel agents by 2034, viewing this meeting as a vital part of that journey.
Highlighted Late-breaking Abstracts
Among the outstanding Late-breaking Abstracts featured at the annual meeting are the following:
- (1316) Monotherapy clinical activity of invikafusp alfa in TMB-H patients from a Phase 1/2 trial by Aurélien Marabelle, MD, PhD.
- (1342) Initial safety and efficacy evaluations of mRNA-LNP MT-302 in solid tumors, presented by Rasha Cosman, BSc (Med), MBBS, FRACP.
- (1348) Results from the HARMONi-A study comparing ivonescimab plus chemotherapy versus chemotherapy alone in patients with EGFR+ NSCLC by Li Zhang, MD.
- (1305) Coformulation of favezelimab with pembrolizumab in neoadjuvant therapy for cSCC by Matteo Carlino, MBBS, PhD, BMedSC, FRACP.
- (1346) Study of lenvatinib combined with pembrolizumab in Merkel cell carcinoma by Kenneth Tsai, MD, PhD.
- (1327) Evaluation of RP1 plus nivolumab in anti-PD-1-failed melanoma by Trisha Wise-Draper, MD, PhD.
- (1328) Efficacy of SSGJ-707, a PD-1/VEGF bispecific antibody, in treating advanced non-small cell lung cancer by Lin Wu, PhD.
- (1310) Findings on ILKN421H as monotherapy and combined with pembrolizumab in advanced solid tumors by Haining Huang, PhD.
- (1325) Open label phase 2 trial of a DNA plasmid vaccine for advanced melanoma, presented by Nermeen Varawalla, MD, PhD, MBA.
- (1336) Final results of Nous-209 monotherapy in Lynch syndrome carriers by Anna Morena D'Alise, PhD.
- (1340) Impacts on immune response from lead-in therapy targeting PD1 and/or LAG3 by Lilit Karapetyan, MD.
- (1345) Initial phase 1a/1b results of STK-012 combined with pembrolizumab and chemotherapy in NSCLC by Adam Schoenfeld, MD.
When and Where to Attend
The sessions for these Late-breaking Abstracts will be held on November 7 and November 8. Specific timing and locations have been designated in the Gaylord National Resort and Convention Center, while virtual attendees can also engage in these vital discussions. Abstracts from the Regular and Young Investigator Award categories will be available on November 4. Additionally, clinical-only abstracts will be ready for review starting November 7.
About the Society for Immunotherapy of Cancer
SITC represents the forefront of cancer immunotherapy advocacy, dedicated to enhancing treatment outcomes for patients globally. Established in 1984, SITC serves an expansive network of professionals, including scientists, clinicians, and patient advocates, through educational programs aimed at fostering collaboration and innovation. By continuously pushing the boundaries of research and clinical practice, SITC is committed to making significant strides toward curing cancer.
Frequently Asked Questions
What is the significance of the SITC Annual Meeting?
The SITC Annual Meeting serves as a platform for presenting groundbreaking research in cancer immunotherapy, featuring expert discussions and late-breaking clinical trials.
How many abstracts were submitted for the 40th SITC Annual Meeting?
There were over 1,300 abstract submissions this year, highlighting a wide array of innovative research in the field.
What types of abstracts are featured in the meeting?
The meeting features both Regular and Late-breaking Abstracts, focusing on recent advancements in cancer treatment methodologies.
When are key sessions taking place during the event?
Key sessions, including oral presentations of Late-breaking Abstracts, are scheduled for November 7 and 8.
How can I learn more about SITC's initiatives?
Interested individuals can visit SITC's website for detailed information on their ongoing projects and annual meetings.
